Bolt Biotherapeutics, Inc. (BOLT)

In June 2025, Bolt completed a 1-for-20 reverse stock split to meet Nasdaq requirements. In October 2025, the company announced a delay in the BDC-4182 clinical data readout to the third quarter of 2026. The company implemented a 50% workforce reduction in October 2025 to conserve capital. In May 2025, the company reported its first-quarter financial results and provided updates on its clinical programs. In August 2025, Bolt reported a 38.5% year-over-year revenue increase in Q2 2025. The stock price decreased from $12.00 per share on November 25, 2024, to $4.71 per share as of November 21, 2025.

Bolt Biotherapeutics does not have products or services subject to typical demand seasonality. The company's revenue primarily stems from research and development collaborations and grants. Its focus is on the long-term development and clinical progression of novel immunotherapies for cancer.

Bolt Biotherapeutics is a clinical-stage immuno-oncology company that develops tumor-targeted therapies. The company's Boltbody™ ISAC platform combines tumor-targeting antibodies with immune-stimulating linker-payloads. Its pipeline includes BDC-3042, an agonist antibody targeting Dectin-2, and BDC-4182, a Boltbody™ ISAC targeting Claudin 18.2. The company also has collaborations with Genmab and Toray Industries.

Bolt Biotherapeutics is headquartered in Redwood City, California. Clinical trials for BDC-4182 are underway in Australia, with plans to expand to other countries in the second half of 2025.

Bolt Biotherapeutics' reputation has been impacted by corporate restructuring and clinical program adjustments. The discontinuation of BDC-1001 development and workforce reductions likely raised concerns. The delay in the BDC-4182 clinical data readout could further affect investor confidence. The company continues to highlight its strategic collaborations and the progress of BDC-3042 and BDC-4182.

Bolt Biotherapeutics is owned by a mix of institutional shareholders and insiders. Institutional shareholders hold approximately 41.89% of the company, while insiders hold a substantial 1,042.40%. Major institutional owners include Vivo Capital, LLC, Sofinnova Investments, Inc., Fidelity Extended Market Index Fund (FSMAX), Fidelity Total Market Index Fund (FSKAX), Pivotal bioVenture Partners Investment Advisor LLC, and Tang Capital Management LLC. Vivo Capital VIII LLC is the largest individual shareholder, owning 5.89 million shares.